Celia Cruz and a Brain Tumor: Remembering the Queen of Salsa

What was reported

Celia Cruz was the Cuban-born singer known worldwide as the Queen of Salsa, and for the shout that punctuated her performances: "¡Azúcar!"

NPR reported her death in July 2003 in a single clear line. Cruz, "who helped define the sound of Afro-Cuban music, dies of a brain tumor at the age of 77."

The type of tumor was not made public, and this page will not assign one. What is worth explaining is the category, because brain tumors work differently from cancers anywhere else in the body.

Why the brain is a special case

Two facts shape everything about these tumors.

First, the skull does not stretch. A growth of a few centimeters anywhere else may cause no trouble for months. Inside a closed bony box, the same growth raises pressure and pushes healthy tissue aside.

Second, function is local. The consequences of a tumor depend less on its size than on its address. A small mass in the speech area produces obvious symptoms. A larger one in a quieter region may produce almost nothing for a while.

That is also why surgery here is a balancing act. The National Cancer Institute (NCI) puts it directly: complete or near-complete removal is attempted "within the constraints of preserving neurological function."

Benign does not mean harmless

Elsewhere in the body, a benign tumor is largely a nuisance. In the brain, a benign tumor in the wrong place can be life-threatening, because pressure is the problem rather than invasion.

This is the single most misunderstood point about brain tumors, and it is why a "benign" result still gets close follow-up.

What grows there

NCI ranks the primary types by frequency. Anaplastic astrocytomas and glioblastomas together make up about 38% of primary brain tumors. Meningiomas and related mesenchymal tumors account for about 27%. Pituitary tumors, schwannomas, CNS lymphomas, oligodendrogliomas, and ependymomas follow.

Tumors are graded by the World Health Organization system, from grade I to grade IV. Grade I tumors divide slowly and are often curable with surgery alone. Grade IV tumors divide rapidly, contain dead tissue at their center, and progress quickly. Glioblastoma is grade IV.

Cancers that begin elsewhere can also spread to the brain. Those are treated as the original cancer, not as a primary brain tumor.

How they show up

Seizures are the headline symptom. NCI reports that a seizure is the presenting symptom in roughly 20% of patients with tumors above the tentorium, the sheet of tissue separating the upper brain from the cerebellum. Across all patients with primary brain tumors, about 70% develop seizures at some point.

Other common features NCI lists are headaches, visual changes, nausea, and personality changes.

Get help now

Call 911 or go to an emergency department immediately for:

• A first-ever seizure, at any age
• Sudden weakness, numbness, or drooping on one side of the face or body
• Sudden trouble speaking or understanding speech
• Sudden loss of part of your vision

Those signs point to stroke first, which is itself an emergency. The workup that rules stroke in or out also finds masses.

Book an urgent appointment, within days, for:

• A headache that wakes you from sleep, or is worst on waking and eases after vomiting
• A headache that has been getting steadily worse over weeks and is unlike your usual headaches
• New double vision, or a blind spot you keep bumping into
• A clear change in memory, personality, or behavior that family have noticed over weeks

Most headaches are not tumors. The pattern is what matters: new, progressive, worse lying flat, or paired with any neurological sign.

MRI first, tissue second

MRI with contrast is the imaging test of choice, because it separates soft tissues far better than CT. NCI calls high-quality MRI the diagnostic study of choice for spinal cord lesions as well.

Imaging suggests. Only tissue confirms. NCI states that biopsy confirmation is critical, whether by needle or during an operation to remove the tumor.

The molecular report matters as much as the scan

Modern brain tumor pathology tests the tissue for specific genetic features, and these change the prognosis more than the picture does.

MGMT promoter methylation is a chemical switch that silences a DNA repair gene. When it is switched off, the tumor cannot undo the damage chemotherapy causes, and survival improves.

IDH1 and IDH2 variants are, in NCI's phrase, "powerful independent prognostic factors." Codeletion of chromosome arms 1p and 19q predicts a better response to chemotherapy.

Ask whether these tests were run and what they showed. They are standard now.

Treatment, and its honest limits

Surgery comes first when the tumor can be safely reached. NCI notes that high-volume centers achieve better outcomes, which is a reason to ask how often a center does this operation.

Radiation for malignant gliomas is typically 60 Gy, delivered in 30 sessions. Temozolomide, an oral chemotherapy drug, has replaced older agents as standard.

The numbers show both the progress and the limits. Adding temozolomide to radiation for glioblastoma raised three-year overall survival from 4.4% to 16.0%. Median survival was 18.2 months when MGMT was methylated, and 12.2 months when it was not. For low-grade gliomas with high-risk features, adding PCV chemotherapy raised median survival from 7.8 years to 13.3 years.

For 2025 the American Cancer Society put the count at about 24,820 new brain and nervous system tumors and 18,330 deaths in the US, and NCI's PDQ summary carries that estimate. NCI's own measured figures are an incidence of 6.2 per 100,000 people and a death rate of 4.4 per 100,000.

Every figure above comes from groups of patients studied over time. None of them forecasts what will happen to one person.

Sources

• https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdq
• https://www.npr.org/2003/07/17/1339401/queen-of-salsa-celia-cruz-dies-at-77
• https://www.cancer.org/research/cancer-facts-statistics.html